





Risk Factor Driven Upstream Therapy in Early Atrial Fibrillation

The <u>Routine versus Aggressive upstream rhythm</u> <u>Control for prevention of Early persistent atrial</u> fibrillation in heart failure study

Michiel Rienstra, Anne H. Hobbelt, Marco Alings, Jan G.P. Tijssen, Marcelle D. Smit, Johan Brügemann, Bastiaan Geelhoed, Robert G. Tieleman, Hans L. Hillege, Raymond Tukkie, Dirk J. Van Veldhuisen, Harry J.G.M. Crijns, Isabelle C. Van Gelder, for the RACE 3 Investigators







- Maintenance of sinus rhythm improves AF-related symptoms
- However, maintenance of sinus rhythm is cumbersome due to atrial remodelling, caused by risk factors and diseases underlying AF, and AF itself
- Recognition of the consequences of atrial remodelling has led to the notion that early intervening may prevent AF progression
- Risk factor driven upstream therapy refers to interventions that aim to modify the atrial substrate, and has a favourable effect on risk factors and diseases underlying AF

Netherlands Heart Institute





Hypothesis and trial design



• Hypothesis:

Risk factor driven upstream therapy is superior to conventional therapy for maintenance of sinus rhythm in patients with early persistent AF and HF

RACE 3 trial design:

- Prospective, randomized, open label, superiority trial
- Investigator-initiated
- Multicenter: 14 sites in The Netherlands and 3 in United Kingdom
- Enrolment between 2009 and 2015
- 1 year follow-up











Patients with early persistent AF and HF

Causal treatment of AF and HF

Risk factor driven upstream

Conventional

Upstream therapy consists of:

- 1) Mineralocorticoid receptor antagonist
- 2) Statin
- 3) ACE-inhibitors and/or

angiotensin-receptor blockers


4) Cardiac rehabilitation:

-physical activity -dietary restrictions ECV after 3 weeks

Guideline-recommended rhythm and rate control

7-day Holter at 1-year

funded by the dutch heart foundation





Conclusion and implication



 The RACE 3 study shows that risk factor driven upstream therapy, including treatment of risk factors and change of lifestyle, is effective and feasible to improve maintenance of sinus rhythm in patients with early persistent AF and HF

 The effect of upstream therapy on reduction of risk factors and cardiovascular diseases, instead of atrial remodeling, was favourable







RACE 3 study organisation



Steering committee

I.C. Van Gelder H.J.G.M. Crijns M. Alings M. Rienstra J.G.P. Tijssen M.D. Smit J. Brügemann R.G. Tieleman H.L. Hillege R. Tukkie D.J. Van Veldhuisen

Supported by: Netherlands Heart Foundation Netherlands Heart Institute **Trial and data management** W.J.M. Mol, O. Eriks

Central Holter core lab

J. Haaksma

Secondary end point adjudication committee R.A. Tio, J.P. Van Melle

Statistical analysis committee M. Rienstra, B. Geelhoed, H.L. Hillege, J.G.P. Tijssen, I.C. Van Gelder

Data Safety and Monitoring Board H.J.J. Wellens, A.M. Wilde, Y.M. Pinto

funded by the dutch heart foundation Hartstichting



RACE 3 investigators



The Netherlands:

University Medical Center Groningen, Groningen - I.C. Van Gelder Amphia Hospital, Breda - M. Alings Martini Hospital, Groningen - R.G. Tieleman Admiraal De Ruyter Hospital, Goes - I. Aksoy Ziekenhuisgroep Twente Location Almelo, Almelo, - G.C.M. Linssen Rijnstate Hospital Arnhem - H.A. Bosker Spaarne Hospital, Haarlem - G.J.E. Verdel Radboud University Nijmegen Medical Center, Nijmegen - E. Cramer Maastricht University Medical Center, Maastricht - H.J.G.M. Crijns Tergooi Hospital, Blaricum - R.H.J. Peters Deventer Hospital, Deventer - Y.S. Tuininga Ommelander Hospital Group, Winschoten/Delfzijl, - A. Van Der Galiën/V. Hagens Onze Lieve Vrouwe Gasthuis, Amsterdam - G.S. De Ruiter **United Kingdom:** Birmingham City Hospital, Birmingham - G.Y.H. Lip

Netherlands Heart Institute

Birmingham City Hospital, Birmingham - G.Y.H. L Leeds General Infirmary, Leeds - M. Tayebjee Poole Hospital, Poole - C. Boos

funded by the dutch heart foundation Hartstichting